ATE518845T1 - Optische isomere eines iloperidon-metaboliten - Google Patents

Optische isomere eines iloperidon-metaboliten

Info

Publication number
ATE518845T1
ATE518845T1 AT02767454T AT02767454T ATE518845T1 AT E518845 T1 ATE518845 T1 AT E518845T1 AT 02767454 T AT02767454 T AT 02767454T AT 02767454 T AT02767454 T AT 02767454T AT E518845 T1 ATE518845 T1 AT E518845T1
Authority
AT
Austria
Prior art keywords
optical isomers
iloperidone metabolite
fouoro
isoxazol
piperidin
Prior art date
Application number
AT02767454T
Other languages
German (de)
English (en)
Inventor
Dominique Grimler
Hans Kalkman
Hequn Yin
Original Assignee
Novartis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Pharma Gmbh filed Critical Novartis Pharma Gmbh
Application granted granted Critical
Publication of ATE518845T1 publication Critical patent/ATE518845T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
AT02767454T 2001-08-31 2002-08-30 Optische isomere eines iloperidon-metaboliten ATE518845T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31639001P 2001-08-31 2001-08-31
PCT/EP2002/009700 WO2003020707A1 (en) 2001-08-31 2002-08-30 Optical isomers of an iloperidone metabolite

Publications (1)

Publication Number Publication Date
ATE518845T1 true ATE518845T1 (de) 2011-08-15

Family

ID=23228843

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02767454T ATE518845T1 (de) 2001-08-31 2002-08-30 Optische isomere eines iloperidon-metaboliten

Country Status (9)

Country Link
US (4) US20050020632A1 (https=)
EP (2) EP1425272B1 (https=)
JP (6) JP2005504783A (https=)
AT (1) ATE518845T1 (https=)
CY (2) CY1112039T1 (https=)
DK (2) DK1425272T3 (https=)
ES (2) ES2370634T3 (https=)
PT (2) PT1425272E (https=)
WO (1) WO2003020707A1 (https=)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2436439T3 (es) 2001-10-30 2014-01-02 Novartis Ag Formulaciones de medicamento de liberación lenta de iloperidona con un polímero
BRPI0308696B8 (pt) 2002-03-27 2021-05-25 Axovant Sciences Gmbh composto derivado de quinolina, seu processo de preparação, sua composição farmacêutica e seus usos
GB0216416D0 (en) 2002-07-15 2002-08-21 Novartis Ag Organic compounds
PT1558582E (pt) 2003-07-22 2006-05-31 Arena Pharm Inc Derivados de diaril- e aril-heteroaril-ureia como moduladores do receptor de serotonina 5-ht2a uteis para a profilaxia e tratamento de desordens relacionadas com o mesmo
GB0322994D0 (en) * 2003-10-01 2003-11-05 Novartis Ag Organic compounds
EP1799865B1 (en) 2004-09-30 2012-06-06 Vanda Pharmaceuticals Inc. Methods for the administration of iloperidone
US20100063093A1 (en) 2007-03-28 2010-03-11 Curt Wolfgang Methods for the administration of iloperidone
US8008144B2 (en) 2006-05-11 2011-08-30 Micron Technology, Inc. Dual work function recessed access device and methods of forming
US20070262395A1 (en) 2006-05-11 2007-11-15 Gibbons Jasper S Memory cell access devices and methods of making the same
US20090306137A1 (en) * 2006-05-22 2009-12-10 Wolfgang Curt D Treatment for depressive disorders
US20150259747A1 (en) 2007-03-29 2015-09-17 Vanda Pharmaceuticals Inc. Method of predicting a predisposition to qt prolongation
US9074254B2 (en) 2007-03-29 2015-07-07 Vanda Pharmaceuticals, Inc. Method of predicting a predisposition to QT prolongation
US8198305B2 (en) 2007-04-13 2012-06-12 Concert Pharmaceuticals Inc. 1,2-benzisoxazol-3-yl compounds
ES2569480T3 (es) 2007-05-18 2016-05-11 Vanda Pharmaceuticals Inc. Marcadores genéticos de eficacia de iloperidona en el tratamiento de síntomas psicóticos
EP2198048A2 (en) 2007-09-10 2010-06-23 Vanda Pharmaceuticals Inc. Prediction of qt prolongation based on snp genotype
EP2508177A1 (en) 2007-12-12 2012-10-10 Glaxo Group Limited Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
BRPI0820993A2 (pt) 2007-12-13 2017-05-09 Vanda Pharmaceuticals Inc método e composição para tratar uma condição mediada por alfa adrenoceptor
SI2222300T1 (sl) 2007-12-13 2014-11-28 Vanda Pharmaceuticals Inc. Postopek in sestavek za zdravljenje stanja, posredovanega z receptorjem serotonina
US20110061014A1 (en) 2008-02-01 2011-03-10 Energyhub Interfacing to resource consumption management devices
WO2009123714A2 (en) 2008-04-02 2009-10-08 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
WO2010062321A1 (en) 2008-10-28 2010-06-03 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto
US7824986B2 (en) 2008-11-05 2010-11-02 Micron Technology, Inc. Methods of forming a plurality of transistor gates, and methods of forming a plurality of transistor gates having at least two different work functions
US8999638B2 (en) 2009-04-06 2015-04-07 Vanda Pharmaceuticals, Inc. Method of treatment based on polymorphisms of the KCNQ1 gene
WO2010117941A1 (en) 2009-04-06 2010-10-14 Vanda Pharmaceuticals, Inc. Method of predicting a predisposition to qt prolongation based on abcc2 gene sequence or product thereof
WO2010117937A1 (en) 2009-04-06 2010-10-14 Vanda Pharmaceuticals, Inc. Method of predicting a predisposition to qt prolongation
WO2010117943A1 (en) 2009-04-06 2010-10-14 Vanda Pharmaceuticals, Inc. Method of predicting a predisposition to qt prolongation based on bai3 gene sequence or product thereof
MX2012007365A (es) 2009-12-23 2012-08-15 Lupin Ltd Composiciones farmaceuticas de liberacion lenta de iloperidona.
WO2012032532A1 (en) * 2010-09-07 2012-03-15 Symed Labs Limited "processes for the preparation of 4'-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)piperidino]propoxy]-3'-methoxyacetophenone and intermediates thereof"
WO2012063269A2 (en) 2010-11-12 2012-05-18 Cadila Healthcare Limited Process for preparing iloperidone
CN108938632A (zh) * 2012-03-14 2018-12-07 万达制药公司 用于治疗精神疾病的伊潘立酮代谢物及其应用
WO2016134049A1 (en) 2015-02-17 2016-08-25 Vanda Pharmaceuticals Inc. Iloperidone for the treatment of schizophrenia
WO2016201373A1 (en) 2015-06-12 2016-12-15 Axovant Sciences Ltd. Diaryl and arylheteroaryl urea derivatives useful for the prophylaxis and treatment of rem sleep behavior disorder
WO2017011767A2 (en) 2015-07-15 2017-01-19 Axovant Sciences Ltd. Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease
JP7416831B2 (ja) * 2019-02-21 2024-01-17 アセンタウィッツ ファーマシューティカルズ リミテッド 高エナンチオ選択性第２級アルコールを作製する方法
US11607408B2 (en) 2019-10-15 2023-03-21 Vanda Pharmaceuticals Inc. Method of treatment of schizophrenia
WO2023201182A1 (en) 2022-04-13 2023-10-19 Vanda Pharmaceuticals Inc. Treatment of parkinson's disease and parkinson's disease psychosis
WO2024137439A1 (en) 2022-12-19 2024-06-27 Vanda Pharmaceuticals Inc. Dosage regime of iloperidone for treating bipolar i disorder and schizophrenia
AU2024278999A1 (en) 2023-06-02 2025-11-13 Vanda Pharmaceuticals Inc. Method of treatment with iloperidone

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4804663A (en) * 1985-03-27 1989-02-14 Janssen Pharmaceutica N.V. 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
US5158952A (en) * 1988-11-07 1992-10-27 Janssen Pharmaceutica N.V. 3-[2-[4-(6-fluoro-1,2-benzisoxozol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9 tetrahydro-9-hydroxy-2-methyl-4H-pyrido [1,2-a]pyrimidin-4-one, compositions and method of use
US5776963A (en) 1989-05-19 1998-07-07 Hoechst Marion Roussel, Inc. 3-(heteroaryl)-1- (2,3-dihydro-1h-isoindol-2-yl)alkyl!pyrrolidines and 3-(heteroaryl)-1- (2,3-dihydro-1h-indol-1-yl)alkyl!pyrrolidines and related compounds and their therapeutic untility
US5364866A (en) * 1989-05-19 1994-11-15 Hoechst-Roussel Pharmaceuticals, Inc. Heteroarylpiperidines, pyrrolidines and piperazines and their use as antipsychotics and analetics
ES2076253T3 (es) 1989-05-19 1995-11-01 Hoechst Roussel Pharma N-(ariloxialquil)-heteroarilpiperidinas y -heteroarilpiperazinas, un procedimiento para su preparacion y su uso como medicamentos.
JPH05286868A (ja) 1992-04-03 1993-11-02 Kiyoshi Okawa 制がん剤複合体およびそのスクリーニング法
US5889006A (en) * 1995-02-23 1999-03-30 Schering Corporation Muscarinic antagonists
US6172099B1 (en) * 1997-07-03 2001-01-09 Asahi Kasei Kogyo Kabushiki Kaisha Tricyclic compounds having saturated rings and medicinal compositions containing the same
AU2003268026A1 (en) 2002-07-30 2004-02-16 Peter Migaly Combination therapy for depression, prevention of suicide, and varous medical and psychiatric conditions

Also Published As

Publication number Publication date
EP2305656B1 (en) 2012-10-24
PT1425272E (pt) 2011-10-19
PT2305656E (pt) 2013-01-10
EP1425272A1 (en) 2004-06-09
ES2398434T8 (es) 2017-10-09
EP1425272B1 (en) 2011-08-03
CY1112039T1 (el) 2015-11-04
DK2305656T3 (da) 2013-02-11
JP2015227368A (ja) 2015-12-17
JP2010100633A (ja) 2010-05-06
JP2013116905A (ja) 2013-06-13
WO2003020707A1 (en) 2003-03-13
US20130296366A1 (en) 2013-11-07
US20110201646A1 (en) 2011-08-18
US20050020632A1 (en) 2005-01-27
US20090176739A1 (en) 2009-07-09
CY1113550T1 (el) 2016-06-22
ES2370634T3 (es) 2011-12-21
EP2305656A1 (en) 2011-04-06
DK1425272T3 (da) 2011-11-21
JP2015214577A (ja) 2015-12-03
JP2005504783A (ja) 2005-02-17
HK1156309A1 (en) 2012-09-07
JP2013227335A (ja) 2013-11-07
ES2398434T3 (es) 2013-03-19
US8314129B2 (en) 2012-11-20
US7977356B2 (en) 2011-07-12
HK1066536A1 (en) 2005-03-24

Similar Documents

Publication Publication Date Title
ATE518845T1 (de) Optische isomere eines iloperidon-metaboliten
PE20080360A1 (es) Derivados 4-bencilftalazinona 2-sustituidos como antagonistas de histaminas h1 y h3
JP2010519243A5 (https=)
NO20051965D0 (no) Nye piperidinderivater for anvendelse ved behandling av kemokinmedierte sykdomstilstander.
DE502004009532D1 (de) Fungizide ternäre wirkstoffkombinationen
NO20062370L (no) Amidderivater
NO341632B1 (no) Ny polymorf form av 5-klor-N({(5S)-2-okso-3[4-(3-okso-4-morfolinyl)-fenyl]-1,3-oksazolidin-5-yl}-metyl)-2-tiofenkarboksamid
HRP20130174T1 (hr) Derivati pirimidina za lijeäśenje astme, kopb, alergijskog rinitisa, alergijskog konjuktivitisa, atopijskog dermatitisa, karcinoma, hepatitisa b, hepatitisa c, hiv, hpv, bakterijskih infekcija i dermatoze
ATE512961T1 (de) Amorphes nebivolol hydrochlorid und seine herstellung
RU2010134361A (ru) Производные изоксазола в качестве модуляторов 11-бета-гидроксистероиддегидрогеназы 1 типа
ATE544756T1 (de) Substituierte carbinolverbindungen
HRP20080446T3 (en) Monohydrochloride salt of 1-[3-[3-(4-chlorophenyl)propoxy]propyl]-piperidine
PE20091431A1 (es) Compuestos derivados de azetidinas, su preparacion y su aplicacion en terapeutica
ATE455103T1 (de) Als antikoagulationsmittel geeignete phenylglycinamid- und pyridylglycinamidderivate
NO20065327L (no) Fremgangsmate for fremstilling av derivarer av 5-'4-(2-hydroksy-propyl)-3,5-dihydro-3H'1, 2,4(triazin-2-yl)-benzamid.
AR049699A1 (es) Derivados de pirimidina
JP2010143943A5 (https=)
RU2005131172A (ru) Производные хинолионона/бензоксазинона и их применение
JP2013510155A5 (https=)
AR058760A1 (es) Derivados de aril -isoxasol -4-il- imidazol
DE602004009079D1 (de) Carbostyril-derivative zur beschleunigten speichelabsonderung
NO20051089L (no) Bredspektrede 2-amino-benzotiazol-sulfonamid-HIV-proteaseinhibitorer
NO20070972L (no) Benzyloksyderivater som MAOB-inhibitorer
WO2007066163A3 (en) Optically active carbamates, process for preparation thereof and use thereof as pharmaceutical intermediates
DE602006010329D1 (de) Verfahren zur herstellung eines indolon-derivats

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1425272

Country of ref document: EP